PUR — Pure Biologics SA Cashflow Statement
0.000.00%
- PLN26.10m
- PLN40.37m
Annual cashflow statement for Pure Biologics SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
| 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M | 
| Source: | ARS | ARS | ARS | ARS | ARS | 
| Standards: | PAS | PAS | PAS | PAS | PAS | 
| Status: | Final | Final | Final | Final | Final | 
| Net Income/Starting Line | -11.8 | -11.8 | -25.6 | -35.7 | -19.4 | 
| Depreciation | |||||
| Non-Cash Items | 4.1 | 3.01 | 4.76 | 7.42 | 1.03 | 
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.19 | -18.2 | 0.955 | -0.772 | 7.27 | 
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.35 | -24 | -17.4 | -23.3 | -10.8 | 
| Capital Expenditures | -0.561 | -0.673 | -5.76 | -0.176 | — | 
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | -27.8 | 21.1 | 0.567 | 3.56 | 
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.561 | -28.5 | 15.3 | 0.391 | 3.56 | 
| Financing Cash Flow Items | -0.349 | -0.227 | -0.329 | -3.11 | -0.073 | 
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -3.05 | 49.7 | -1.88 | 24.2 | 3.98 | 
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.96 | -2.78 | -3.92 | 1.35 | -3.29 |